French price cuts will hit innovators, generics and wholesalers
This article was originally published in Scrip
Executive Summary
France, Europe's second-largest pharmaceutical market with sales growing by 2% to $40.75 billion for the 12 months to the second quarter of 2010, is introducing a number of measures to contain its healthcare spending for 2011, with pharmaceuticals taking a large hit. The measures will affect R&D firms, as well as the generics sector and wholesalers.